Inovelon

Rufinamide, the active ingredient in Inovelon, is an anticonvulsant presented as an oral tablet for oral use. It is indicated for the treatment of Lennox‑Gastaut syndrome and other refractory epilepsies in patients who require adjunctive seizure control in children and adults.

GNH USA supplies Inovelon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring consistent quality, regulatory compliance, and reliable logistics for global healthcare providers. Our network spans multiple continents, facilitating timely delivery and support for therapeutic programs.

Rufinamide is used as an adjunctive therapy in the management of severe epilepsy syndromes, particularly those resistant to standard treatments.

Lennox‑Gastaut syndrome: reduces the frequency of multiple seizure types in patients with this refractory epilepsy. Other refractory epilepsies: provides additional seizure control when conventional antiepileptic drugs are insufficient.

Rufinamide may cause a range of adverse reactions, which vary in frequency and severity.

Common Side Effects: - Dizziness: transient sensation of lightheadedness. - Fatigue: persistent tiredness affecting daily activities. - Nausea: mild to moderate upset stomach. - Somnolence: increased sleepiness during the day. - Headache: mild to moderate head pain. - Decreased appetite: reduced desire for food.

Serious or Rare Side Effects: - Severe skin reactions: such as Stevens‑Johnson syndrome. - Suicidal thoughts: emergence of depressive symptoms or ideation. - Hepatic dysfunction: elevated liver enzymes or hepatitis. - Blood dyscrasias: abnormal blood counts. - Cardiac arrhythmias: irregular heart rhythms. - Anaphylactic reaction: acute allergic response requiring emergency care.

When prescribing Rufinamide, clinicians should consider several safety aspects to minimize risk.

Renal impairment: adjust dose and monitor renal function. Hepatic impairment: monitor liver enzymes and consider dose modification. Concomitant enzyme inducers: be aware that drugs like carbamazepine may lower rufinamide levels. Pregnancy: potential risk is unknown; avoid unless clearly needed. Monitor for mood changes: watch for signs of depression or suicidal ideation. Store at ambient temperature: keep in original packaging, protect from moisture and excessive heat.

Rufinamide can interact with other medications, influencing its efficacy or safety.

Major Interactions (Avoid): - Carbamazepine: reduces rufinamide plasma concentrations. - Phenobarbital: decreases rufinamide exposure. - Phenytoin: lowers rufinamide levels.

Moderate Interactions (Monitor Closely): - Oral contraceptives: may reduce hormonal efficacy. - CYP3A4 inhibitors: can increase rufinamide concentrations. - CNS depressants: additive sedation may occur.